baculoviru
bv
system
use
product
variou
vaccin
candid
induc
humor
cellmedi
crossimmun
viral
infect
previous
demonstr
wildtyp
wt
bv
autographa
californica
multipl
nuclear
polyhedrosi
viru
acmnpv
bvinfect
dendrit
cell
dc
exert
natur
killer
nk
celldepend
antimetastat
effect
mice
cell
independ
antimetastat
effect
involv
bv
directli
activ
nk
cell
induc
upregul
nk
cell
effector
function
tumor
tolllik
receptor
depend
manner
addit
bv
shown
suppress
liver
injuri
fibrosi
vivo
induct
interferon
ifn
molinari
et
al
also
report
bv
carri
ovalbumin
ova
capsid
protein
induc
antitumor
immun
hand
studi
sever
research
group
demonstr
high
titer
recombin
bv
rbv
antigen
induc
specif
antibodi
highlevel
transgen
express
rbv
vector
well
suit
antitumor
therapi
test
anim
tumor
model
therefor
present
studi
rbvbase
combin
vaccin
develop
express
fragment
c
frc
tetanu
toxin
contain
promiscu
mhc
iibind
sequenc
peptid
function
mhc
pathway
potenti
antitumor
vaccin
evalu
pcr
product
ova
frcdna
fragment
insert
kpni
bglii
site
cag
promot
construct
recombin
plasmid
respect
fig
insert
frcova
plasmid
confirm
rtpcr
analysi
addit
file
figur
product
frcovabv
rbv
wtbv
describ
materi
hightit
virus
obtain
rang
ffuml
structur
frcova
rbvgenom
dna
confirm
western
blot
analysi
rbvinfect
cell
fig
rbv
vaccin
express
tetanu
toxin
frc
contain
promiscu
mhc
iibind
sequenc
peptid
function
mhc
pathway
construct
frcovabv
rbv
specif
mhc
pathway
evalu
ovaspecif
secret
vivo
ovaspecif
tcell
splenocyt
analyz
use
elispot
tcell
assay
day
intramuscular
inject
rbv
wtbv
pb
day
mice
fig
display
fig
restimul
rbvimmun
spleen
cell
ova
peptid
result
higher
level
ovaspecif
compar
cell
treat
wtbv
pb
rbvimmun
spleen
cell
treat
control
peptid
gag
level
ovaspecif
decreas
observ
wtbv
control
hand
determin
tcell
assay
rbv
wtbv
group
show
higher
level
tcell
pb
control
group
fig
result
suggest
rbv
effici
activ
tcellmedi
respons
wtbv
group
experi
perform
verifi
whether
rbv
could
induc
antitumor
immun
establish
subcutan
tumor
mice
first
classic
prophylact
vaccin
examin
experiment
design
demonstr
fig
mice
immun
rbv
wtbv
pb
day
prior
inocul
cell
growth
tumor
rbv
group
inhibit
compar
observ
pb
control
group
tumor
develop
wherea
tumor
growth
wtbv
group
differ
control
day
inhibit
note
thereaft
fig
c
determin
antitumor
effect
rbv
growth
therapeut
vaccin
perform
fig
surviv
rate
mice
inocul
cell
day
follow
immun
rbv
wtbv
pb
day
calcul
surviv
time
mice
immun
rbv
significantli
longer
mice
inocul
control
wtbv
fig
result
indic
rbvmediat
protect
tumor
may
use
antitumor
immunotherapi
tool
viral
vector
vaccin
establish
date
human
viral
vector
continu
give
rise
problem
associ
biosafeti
toxic
furthermor
inactiv
vaccinemedi
immun
shortliv
predominantli
humor
poor
cellmedi
immun
among
viral
vector
adenoviru
adenoassoci
viru
aav
much
lower
risk
insert
mutagenesi
test
oncolyt
virotherapi
adenovir
vector
elicit
antivir
immun
respons
follow
first
administr
larg
dose
vector
viru
highli
immunogen
reaction
might
preclud
use
vector
make
subsequ
use
less
effect
recent
certain
nonhuman
viral
vector
includ
bv
explor
gene
therapi
vector
previou
studi
focus
use
bv
vaccin
gene
therapi
bv
replic
mammalian
cell
low
cytotox
favor
biosafeti
featur
kim
et
al
use
bv
deliveri
system
introduc
telomeras
revers
transcriptas
tert
potenti
tumorassoci
antigen
cancer
immunotherapi
immunocompet
mice
bvtert
induc
cell
specif
tert
nk
cell
activ
mous
splenocyt
sinc
surfac
modif
bv
envelop
vesicular
stomat
g
vsvg
membran
protein
improv
bv
transduct
vitro
vivo
display
vsv
g
protein
vsvg
heterolog
peptideprotein
via
anchor
wide
adopt
method
enhanc
vitro
vivo
gene
transduct
effici
recombin
baculovirus
use
method
cgkrk
tumorhom
peptid
origin
identifi
vivo
screen
phage
display
librari
fusion
protein
success
incorpor
bud
virion
show
bind
abil
human
breast
carcinoma
hepatocarcinoma
cell
improv
two
fivefold
fusion
protein
inhibit
viru
bide
transduct
free
solubl
peptid
solubl
peptid
induc
death
cultur
cancer
cell
inhibit
tumor
growth
mice
implant
xenograft
tumor
author
describ
bv
express
exert
effect
similar
solubl
addit
allow
effici
bv
transduct
wtbv
shown
immunostimul
releas
inflammatori
cytokin
includ
inf
mammalian
cell
confer
protect
lethal
viru
infect
mice
abe
et
al
report
wtbv
activ
proinflammatori
cytokin
periton
macrophag
cell
splenic
dc
murin
macrophag
cell
line
pathway
bv
genom
induc
innat
immun
respons
subsequ
previou
studi
demonstr
bv
induc
function
matur
human
monocytederiv
dc
hcd
activ
human
nk
cell
via
bvhcd
furthermor
show
bv
directli
activ
nk
cell
via
bvdc
might
therefor
use
immunotherapi
tool
viral
infect
malign
particularli
use
associ
current
virotherapi
achiev
effect
result
host
innat
acquir
adapt
immun
also
strongli
induc
rbv
vector
present
studi
anticanc
combin
therapi
investig
use
rbvbase
combin
vaccin
express
frc
tetanu
toxin
ova
peptid
frcova
synergist
action
antitumor
vaccin
evalu
investig
frcovabv
rbv
wtbv
construct
use
tumor
mous
model
studi
aim
examin
whether
product
frcovabv
rbv
ovaspecif
releas
elispot
tcell
assay
use
fig
respons
ova
peptid
rbv
exhibit
significantli
higher
ovaspecif
level
wtbv
group
howev
compar
rbvimmun
spleen
cell
restimul
control
gag
peptid
level
ovaspecif
product
reduc
level
observ
wtbv
control
hand
tcell
assay
rbv
wtbv
group
display
higher
level
tcell
pb
control
group
present
studi
question
whether
rbv
induc
effect
antitumor
immun
cell
mice
address
classic
prophylact
therapeut
vaccin
examin
vaccin
result
inhibit
tumor
growth
increas
surviv
time
respons
inocul
rbv
fig
c
result
indic
antitumor
effect
rbv
tumor
mediat
specif
antifrcova
immun
respons
result
present
studi
reveal
rbvbase
combin
vaccin
express
frcova
suffici
induc
antitumor
immun
mice
establish
tumor
effect
wtbv
addit
rbv
show
signific
antitumor
effect
classic
prophylact
therapeut
vaccin
furthermor
baculoviru
sever
attract
advantag
good
biosafeti
larg
capac
foreign
gene
better
posttransl
modif
gene
deliveri
vehicl
therefor
rbv
potenti
use
effici
antimetastat
agent
expect
advantag
futur
develop
antitumor
therapi
femal
mice
week
old
purchas
japan
slc
inc
maintain
human
specif
pathogenfre
condit
accord
rule
regul
institut
committe
chiba
institut
technolog
narashino
japan
spodoptera
frugiperda
insect
cell
cultur
ii
cultur
medium
invitrogen
thermo
fisher
scientif
inc
cell
cultur
dmem
sigmaaldrich
merck
kgaa
supplement
fetal
bovin
serum
fb
thermo
fisher
scientif
inc
uml
penicillin
streptomycin
sigmaaldrich
merck
kgaa
cell
deriv
american
type
cultur
collect
maintain
complet
rpmi
medium
gibco
thermo
fisher
scientif
inc
supplement
heatinactiv
fetal
calf
serum
mm
lglutamin
penicillin
uml
streptomycin
mgml
adjust
contain
gl
sodium
bicarbon
gl
glucos
mm
hepe
mm
sodium
pyruv
mm
mgml
atmospher
dna
vaccin
contain
gene
encod
first
domain
p
dom
construct
pcr
amplif
ntermin
domain
sequenc
p
frc
use
forward
primer
kpn
idomf
revers
primer
bgl
iidomr
contain
ova
peptid
sequenc
clone
gener
mluibamhidigest
dna
fragment
insert
mluibamhidigest
pcr
product
frcova
insert
kpn
bgl
ii
site
cag
promot
pcr
product
ova
fcdna
fragment
clone
construct
recombin
plasmid
plasmid
propag
escherichia
coli
purifi
qiagen
plasmid
mini
kit
qiagen
gmbh
accord
manufactur
protocol
insert
frcova
plasmid
confirm
rtpcr
analysi
total
rna
isol
rbvinfect
cell
addit
file
figur
sequenc
analysi
acmnpv
rbv
propag
cell
cultur
tmnfh
medium
bd
bioscienc
contain
kanamycin
fb
accagfrcova
acmnpv
purifi
describ
previous
viral
titer
determin
plaqu
assay
total
rna
extract
cell
use
mammalian
total
rna
miniprep
kit
sigmaaldrich
merck
kgaa
accord
manufactur
protocol
cdna
prepar
use
revertra
toyobo
life
scienc
pcr
frcova
gapdh
perform
use
takara
ex
hotstart
version
takara
bio
inc
primer
sequenc
follow
gapdh
forward
revers
pcr
condit
consist
initi
denatur
step
min
follow
cycl
denatur
anneal
extens
cell
cellswel
plate
transfect
plasmid
use
roch
diagnost
h
post
transfect
rtpcr
use
analyz
insert
frcova
gene
plasmid
detail
frcova
rna
analysi
describ
previou
section
cell
infect
moi
rbv
pfu
transfect
use
h
post
infect
cell
lyse
lysi
buffer
mm
trishcl
ph
dithiothreitol
sd
glycerol
cell
extract
separ
sdspage
protein
blot
onto
pvdf
membran
roch
molecular
diagnost
ova
protein
detect
use
antiova
antibodi
cat
dilut
sigmaaldrich
merck
kgaa
horseradish
peroxidaseconjug
antimous
igg
secondari
antibodi
dilut
use
ecl
plu
detect
system
ge
healthcar
gapdh
use
intern
control
wtbv
pfu
rbv
frcovabv
pfu
pb
administ
mice
via
intramuscular
inject
inject
repeat
day
day
post
inject
mice
sacrif
spleen
isol
dissoci
mous
spleen
perform
use
gentlemac
dissoci
miltenyi
biotec
gmbh
accord
manufactur
protocol
follow
centrifug
min
room
temperatur
supernat
fluid
remov
pellet
resuspend
cultur
medium
desir
concentr
aliquot
suspend
cell
use
assay
cell
quantiti
cell
suspens
adjust
final
densiti
cellsml
splenocyt
use
elispot
tcell
assay
releas
measur
use
commerci
mous
elispot
readi
set
go
kit
ebiosci
thermo
fisher
scientif
inc
accord
manufactur
instruct
mous
spleen
cell
cellswel
ad
pvdf
plate
merck
kgaa
precoat
captur
mous
monoclon
antibodi
plate
treat
ova
peptid
genscript
inc
gag
peptid
consensu
group
sequenc
aid
research
refer
reagent
program
divis
aid
nation
institut
allergi
infecti
diseas
nation
institut
health
concentr
inocul
h
plate
wash
three
time
pbstween
incub
biotinyl
monoclon
antibodi
h
room
temperatur
follow
anoth
round
wash
plate
incub
streptavidinconjug
alkalin
phosphatas
h
room
temperatur
plate
wash
elispot
wash
buffer
well
incub
aec
substrat
solut
h
plate
airdri
overnight
room
temperatur
dark
elispot
plate
read
zellnet
consult
inc
tcell
assay
carri
use
commerci
bd
plu
fixationpermeabil
kit
bd
bioscienc
accord
manufactur
protocol
mous
spleen
cell
cellswel
incub
ova
peptid
ml
brefeldin
ml
h
subsequ
mous
spleen
cell
incub
monoclon
antibodi
ebiosci
thermo
fisher
scientif
inc
min
ice
presenc
monoclon
antibodi
block
bind
follow
block
cell
treat
fac
buffer
centrifug
min
resuspend
cell
treat
fixationpermeabil
solut
min
wash
twice
bd
buffer
cell
incub
fitcantimous
ebiosci
thermo
fisher
scientif
inc
min
dark
wash
twice
ml
bd
permwash
buffer
plate
incub
peconjug
antimous
bd
bioscienc
min
dark
wash
twice
ml
fac
buffer
cell
pellet
suspend
fac
buffer
analyz
facscalibur
instrument
cellquest
pro
softwar
bd
bioscienc
prophylact
assess
mice
immun
singl
intramuscular
inject
wtbv
pfu
rbv
pfu
pb
day
cell
cellsmous
transplant
subcutan
immun
mice
tumor
volum
measur
everi
day
week
use
slide
calip
calcul
accord
follow
formula
tumor
volum
length
mm
assess
therapeut
effect
mice
subcutan
inject
day
cell
cellsmous
surviv
rate
mice
treat
rbv
pfu
wtbv
pfu
pb
day
evalu
oneway
analysi
varianc
follow
tukey
post
hoc
test
mannwhitney
u
test
conduct
pairwis
comparison
calcul
perform
use
statistica
program
statsoft
inc
result
present
median
mean
valu
standard
deviat
p
consid
indic
statist
signific
differ
